This increase in maximum tubular glucose transport is attributed to up-regulation of SGLT2 and therefore SGLT2 inhibitors would induce greater levels of urinary glucose excretion in patients with diabetes compared to individuals with normal glucose metabolism [61,62]. The gene discussed is SLC5A2; the disease is diabetes mellitus.